Key highlights

  • Firebrick Pharma (ASX:FRE) decided to pursue US retail pharmacy distribution for Nasodine.
  • The company appointed a US commercial lead and launched Nasodine Sinus Rinse in October.
  • September-quarter cash operating expenses fell to AUD 729,000.

Shares in Firebrick Pharma (ASX:FRE) were quoted at AUD 0.027 on 20 November 2026, down 10.00%. The S&P/ASX 200 benchmark also declined during trading. The company, a pharmaceutical company developing and commercialising Nasodine products, reported plans to enter US pharmacy retail and a new Nasodine product launch on 23 October 2026.

A retail decision following US online sales

Firebrick Pharma’s 23 October 2026 activities report revisited its September decision to enter the US retail pharmacy market with Nasodine products. Management said the decision followed online sales growth and attendance at an August pharmacy retail trade event in Boston. Firebrick formulated a plan to pursue distribution through retail channels and appointed US-based director Al Moghaddam as US Commercial Director. The role covers retail Marketing and channel development for the Nasodine range. The report describes Firebrick’s entry strategy. Previous retail experience of its commercial lead and an active retail sales plan are distinct from contracted distribution or orders.

A product launch after the end of the quarter

Firebrick continued work on the next product in its range during the September quarter. On 21 October it announced the launch of Nasodine Sinus Rinse. The timing places the release after the 30 September balance date and before publication of the quarterly update. The launch adds a product milestone alongside the strategy to reach retail pharmacies. Online sales activity supplied one input to management’s decision, while the new product and retail effort will have their own sales and operating timetables. Future activity will depend on securing distribution, availability and customer purchasing in the channels the company is pursuing.

A wider product range alongside a wider channel

Firebrick reported that it had added Nasodine Throat Spray and Sinus Rinse during 2026, broadening the range beyond the original Nasodine Nasal Spray. It listed the United States, Singapore and Fiji as markets where the nasal spray had launched, and Indonesia and the Philippines as markets where it was approved for marketing. Those statements concern the nasal spray. The October product milestone concerns the rinse, with the company’s US pharmacy initiative involving the wider Nasodine range. The geographic status, product launch and retail entry strategy each refer to different commercial steps. Firebrick’s reported growth in US online sales relates to the existing business, while retail distribution would add a separate set of relationships and sales measures. A future company update could identify which products reach that channel and how their availability progresses across stores or pharmacy groups.

Research expenditure and quarterly cash operating costs

Cash operating expenses totalled AUD 729,000 in the September quarter, AUD 110,000 below the June quarter. Firebrick attributed most of the reduction to Research and Development costs, which fell AUD 98,000 quarter on quarter. It received an AUD 293,000 research and development tax incentive for eligible FY26 expenditure. The company linked the payment to AUD 673,000 of reported research and development costs associated with new products in the range. The incentive is a Cash Receipt connected to earlier expenditure and sits separately from sales receipts. Related-party payments of AUD 285,000 comprised executive salaries and non-executive director fees. The company reported that payments to related parties and their associates were AUD 35,000 lower than in June, attributing the change to the timing of statutory payments.

Sales receipts and a different channel mix

Sales receipts fell by AUD 39,000 from the June quarter. The company attributed the quarter-on-quarter move to seasonal factors and described annualised sales growth, particularly in the United States. A new retail channel can involve different order patterns, delivery requirements and sales timing from direct online transactions. The shift makes it useful to measure actual channel sales and receipts as new arrangements are implemented. The September figures mostly describe the Business before the October product launch. They also include the tax incentive, which needs to be distinguished from customer payments when comparing the company’s Cash Flow across periods.

What retail execution will show

The next commercial outcomes include any new retail distribution arrangements and sales from the expanded product range. Subsequent reporting can indicate the balance between customer receipts and the resources used to support more products and a broader channel. The company has set out its entry plan, while its September figures provide a baseline before the expansion.